rs33985472

chr11-5225485-T-C

Variant summary

Our verdict is Likely pathogenic. Variant got 7 ACMG points: 8P and 1B. PP5_Very_Strong BP4

The NM_000518.5(HBB):c.*113A>G variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).

• Frequency:
  • Genomes: not found (cov: 33)
  • Exomes 𝑓: 0.0000012 (0 hom.)
• Consequence: HBB NM_000518.5 3_prime_UTR
• Clinical Significance: Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:4 O:1
• Conservation: PhyloP100: 1.29

Genes affected

HBB (HGNC:4827): (hemoglobin subunit beta) The alpha (HBA) and beta (HBB) loci determine the structure of the 2 types of polypeptide chains in adult hemoglobin, Hb A. The normal adult hemoglobin tetramer consists of two alpha chains and two beta chains. Mutant beta globin causes sickle cell anemia. Absence of beta chain causes beta-zero-thalassemia. Reduced amounts of detectable beta globin causes beta-plus-thalassemia. The order of the genes in the beta-globin cluster is 5'-epsilon -- gamma-G -- gamma-A -- delta -- beta--3'. [provided by RefSeq, Jul 2008]

(HGNC:):

ACMG classification

Verdict is Likely_pathogenic. Variant got 7 ACMG points.

• PP5: Variant 11-5225485-T-C is Pathogenic according to our data. Variant chr11-5225485-T-C is described in ClinVar as [Likely_pathogenic]. Clinvar id is 15473.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr11-5225485-T-C is described in Lovd as [Pathogenic].
• BP4: Computational evidence support a benign effect (BayesDel_noAF=-0.57).. Strength limited to SUPPORTING due to the PP5.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	MANE	UniProt
HBB	NM_000518.5	c.*113A>G		3_prime_UTR_variant	3/3	ENST00000335295.4

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	TSL	MANE	Appris	UniProt
HBB	ENST00000335295.4	c.*113A>G		3_prime_UTR_variant	3/3	1	NM_000518.5	P1
HBB	ENST00000647020.1	c.*113A>G		3_prime_UTR_variant	3/3			P1
HBB	ENST00000633227.1	c.*373A>G		3_prime_UTR_variant, NMD_transcript_variant	3/3	3
	ENST00000644706.1			upstream_gene_variant

Frequencies

GnomAD3 genomes Cov.: 33

GnomAD4 exome AF: 0.00000117 AC: 1 AN: 855894 Hom.: 0 Cov.: 12 AF XY: 0.00000222 AC XY: 1 AN XY: 449718

Gnomad4 AFR exome AF: 0.00

Gnomad4 AMR exome AF: 0.00

Gnomad4 ASJ exome AF: 0.00

Gnomad4 EAS exome AF: 0.00

Gnomad4 SAS exome AF: 0.00

Gnomad4 FIN exome AF: 0.00

Gnomad4 NFE exome AF: 0.00

Gnomad4 OTH exome AF: 0.0000248

GnomAD4 genome Cov.: 33

ClinVar

Significance: Pathogenic/Likely pathogenic

Submissions summary: Pathogenic:4 Other:1

Revision: criteria provided, multiple submitters, no conflicts

Submissions by phenotype

beta Thalassemia Pathogenic:2 Other:1

Pathogenic, criteria provided, single submitter	clinical testing	Women's Health and Genetics/Laboratory Corporation of America, LabCorp	Jul 19, 2021	Variant summary: HBB c.*113A>G (a.k.a. Poly(A) AATAAA>AATAAG) variant involves the alteration of a non-conserved nucleotide located at the last nucleotide of the polyA tail. Analysis of RNA derived from peripheral blood of patients carrying this mutation revealed several species of extended transcripts, indicating that the mutation interferes with mRNA cleavage (Rund_1991). The variant was absent in 31396 control chromosomes (gnomAD). It has been reported in numerous BTHAL patients (both intermediate and major types) (example: Rund_1991, Shaji_2003, Khelil_2010, and Kalla_1997). Rund et al noted that this mutation leads to a moderate Beta+thalassemia phenotype and patients who are compound heterozygotes for this mutation and a beta0 mutation require transfusions less frequently than most patients with Beta+thalassemia major (Rund_1991). Two other ClinVar submitters (evaluation after 2014) cite the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
Likely pathogenic, criteria provided, single submitter	clinical testing	Counsyl	Apr 04, 2017	- -
not provided, no classification provided	literature only	GeneReviews	-	- -

not provided Pathogenic:1

Pathogenic, criteria provided, single submitter

clinical testing

Invitae

Oct 17, 2023

This variant occurs in a non-coding region of the HBB gene. It does not change the encoded amino acid sequence of the HBB protein. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individuals with autosomal recessive beta thalassemia (PMID: 1374896, 24719849). This variant is also known as Poly A (AATAAA>AATAAG). ClinVar contains an entry for this variant (Variation ID: 15473). Studies have shown that this variant alters HBB gene expression (PMID: 1374896). For these reasons, this variant has been classified as Pathogenic. -

Beta-plus-thalassemia Pathogenic:1

Pathogenic, no assertion criteria provided

literature only

OMIM

May 15, 1992

- -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
BayesDel_noAF	Benign	-0.57
Cadd	Benign	20
Dann	Benign	0.80

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.0		Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs33985472; hg19: chr11-5246715;